The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India

Abstract

Background Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India. Methods A retro-prospective comparative observational study was conducted in symptomatic COVID19 patients to evaluate the impact of Casirivimab and Imdevimab antibody cocktail in the high-risk population. Through an extensive data retrieval for 6 months, 152 samples were documented and sorted into test (Casirivimab and Imdevimab treated patients, n = 79) and control (Non- Casirivimab and Imdevimab treated individuals, n = 73) subsets. The research had two phases; first, estimation of mechanical ventilation and high flow oxygen requirement and mortality in samples amidst the treatment, and second was the post COVID19 patients' feedback through validated (Cronbach's alpha coefficient = 0.7) questionnaire that evaluated their health and vaccination status, and treatment satisfaction. Results We noticed lesser requisite for mechanical ventilation (6.3%; p < 0.001), high flow oxygen (5.1%; p < 0.001) and no death during Casirivimab and Imdevimab therapy. Meanwhile, non-vaccinated test groups were not on mechanical ventilation and those fully immunized seldom entailed high flow oxygen (test, 6.3%; control, 41.9%, p < 0.01). On evaluating the post COVID19 status of each patient in the study, 90.1% of the test samples were healthy and 97.2% were satisfied with the treatment than those in control group. Conclusions Casirivimab and Imdevimab regimen was clinically beneficial for high risk COVID19 patients than those treated without the antibody cocktail.

Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis

“…Anti-SARS-CoV-2 mABs therapies are generally well-tolerated in patients suffering from COVID-19. 47,[54][55][56][57] Our study has some important limitations. First, a significant publication bias was detected in the present meta-analysis.…”

“…showed that neutralising mABs are safe and not associated with a higher risk of adverse events compared to placebo. Anti‐SARS‐CoV‐2 mABs therapies are generally well‐tolerated in patients suffering from COVID‐19 47,54–57 …”

“…Anti‐SARS‐CoV‐2 mABs therapies are generally well‐tolerated in patients suffering from COVID‐19. 47 , 54 , 55 , 56 , 57 …”

Retrospective Analysis of Neutralizing Antibody Cocktail (Casirivimab and Imdevimab): A Game Changer in Treating Mild COVID-19 Patients

“…However, patients were instructed not to take any vaccine till 90 d after taking the antibody treatment regimen [24,25] . This study also reported a reduction in the need for mechanical ventilation and Intensive Care Unit (ICU) support following CAS and IMD, even for the non-immunized patients which could be owing to efficacy of the antibody cocktail's reduced response to interfering with the vaccine-induced immune response [26] . A similar study was also in agreement with the current findings [27] .…”

Effect of casirivimab-imdevimab on mild COVID-19 patients with diabetes in reducing oxygen supplementation at 28 days: an observational study

“…Aneesh et al in a retro-prospective study showed that need for mechanical ventilation and high flow oxygen requirement were significantly low in casirivimabimdevimab treated patients when compared to patients with standard treatment. 14 There was a case of anaphylaxis in one of the patients who received the drug and it was promptly treated. We recommend giving casirivimab-imdevimab at hospital setup where adequate facilities for resuscitation are available.…”